FDA Approval for EirGen Product EIR-087

EirGen Pharma are delighted to announce that our product EIR-087 has today received approval from US FDA. This highly toxic chemotherapy agent was taken through our R&D pipeline to approval and is the first approved ANDA by FDA for this treatment. This is a highly significant milestone we have achieved and the product is expected to commercialise shortly.